Observational Study for Patients With Hypertrophic Cardiomyopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-06-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational study on patients with hypertrophic cardiomyopathy aims to investigate the correlation between cardiac fibrosis, as indicated by cardiac magnetic resonance, and the prognosis, and further to explore biomarkers for cardiac fibrosis and adverse prognosis of hypertrophic cardiomyopathy. Therefore, endpoints including all-cause mortality, cardiovascular death, ventricular arrythmia, non-fatal stroke, non-fatal myocardial infarction, sudden death, successful cardiopulmonary resuscitation will be evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observational Study for Patients With Dilated Cardiomyopathy

NCT04837612

DCM - Dilated Cardiomyopathy

UNKNOWN

Outcome of Different Pathogenic Mutations in Hypertrophic Cardiomyopathy

NCT03726424

Hypertrophic Cardiomyopathy

UNKNOWN

A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population

NCT06775665

Hypertrophic Cardiomyopathy (HCM)

NOT_YET_RECRUITING

Predictive Factors and Consequences of Myocardial Fibrosis in Hypertrophic Cardiomyopathy

NCT02922517

Hypertrophic Cardiomyopathy

UNKNOWN

HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy

NCT01915615

Hypertrophic Cardiomyopathy

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this observational study on patients with hypertrophic cardiomyopathy, 500 eligible patients, who were diagnosed as hypertrophic cardiomyopathy by echocardiography, will be recruited with a median follow up of 5 years. Patients will be excluded who develop cardiac hypertrophy caused by other factors such as hypertension, diabetes, myocardial amyloidosis, mitochondria cardiomyopathy, congenital heart disease, etc; who have underwent heart transplantation; who are not suitable for the present study due to malignant tumor or severe trauma.

Eligible individuals, identified based on echocardiography and medical records, were invited by phone to a community clinic for visit. For eligible individuals, study data were comprised of a self-administered questionnaire, anthropometric features, laboratory examinations, echocardiographic and/or cardiac magetic resonance data. Anthropometric data were measured by experienced research staff in the morning under standardized conditions. Echocardiographic measuring were performed by three skilled sonographers independently, based on routine protocols on an HP5500 (Phillips Medical System, Boston, Massachusetts, USA) per current guidelines. Venous blood samples were collected in the morning following overnight fasting. Laboratory procedures were performed under standardized conditions.

Endpoints including all-cause mortality, cardiovascular death, sudden death (ICD-Code I46.1, R96), ventricular tachycardia(ICD-code I47.2)/fibrillation/flutter(ICD-code I49.0), hospitalization for heart failure(ICD-Code I50), heart transplatation ((ICD-Code Z94.1), non-fatal stroke(ICD-Code I60, I61, I63, I64), non-fatal myocardial infarction (ICD-Code I21), sudden death (ICD-Code I46.1, R96), successful cardiopulmonary resuscitation (ICD-Code I46.0) will be evaulated.

Across the whole observational study, 50 endpoints are anticipated to occur annually, and therefore the sample size was estimated to be approximately 500 subjects.

Data collection and management will be conducted via electronic data collection (EDC). Source data will be checked regularly to assess the accuracy and completeness. For statistical analysis, For continuous variables are presented as mean±standard deviation (SD), and compared by the Student t-test. Categorical variables were presented as frequency and assessed by the χ2 test. SAS 9.4 for Windows (release 6.11, USA) was utilized for statistical analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HCM - Hypertrophic Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention nor exposure

As an observational study, no intervention nor exposure is interested.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with hypertrophic cardiomyopathy by medical history, physical examination and echocardiography.

Exclusion Criteria

* Patients with cardiac hypertrophy caused by other factors such as hypertension, diabetes, myocardial amyloidosis, mitochondria cardiomyopathy, congenital heart disease, valvular heart disease, etc; Patients who had underwent heart transplatation; Individuals not suitable for the present study due to maligant tumor or severe trauma will be excluded.

Eligible Sex

ALL

Accepts Healthy Volunteers

No